Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

NCT04996017 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

162

Enrollment

OTHER

Sponsor class

Conditions

Mesotheliomas Pleural

Interventions

DRUG: Atezolizumab 1200 mg in 20 ML Injection
DRUG: Placebo

Sponsor

Gruppo Oncologico Italiano di Ricerca Clinica